Peter John Shaw

Peter John Shaw

Auto-generated profile, based on publicly available information

Peter John Shaw

The Children`s Hospital at Westmead, Sydney, Australia

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2004 in Experimental Hematology
Verified
Journal Article
Closed access
EGEliane Gluckman
Eliane Gluckman
VRVanderson Rocha
Vanderson Rocha
william arcesewilliam arcese
william arcese
GMGérard Michel
Gérard Michel
Guillermo F SanzGuillermo F Sanz
Guillermo F Sanz
OGon behalf of the Eurocord Group
on behalf of the Eurocord Group

1 November 2016 in The Lancet Haematology
Verified
Journal Article
Closed access
IBImke H Bartelink
Imke H Bartelink
ALArief Lalmohamed
Arief Lalmohamed
ERElisabeth M L van Reij
Elisabeth M L van Reij
CDChristopher C Dvorak
Christopher C Dvorak
RSRada M Savic
Rada M Savic
JBJaap Jan Boelens
Jaap Jan Boelens

12 November 2012 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
SMS. Matthes‐Martin
S. Matthes‐Martin
TFT. Feuchtinger
T. Feuchtinger
PSP.J. Shaw
P.J. Shaw
DED. Engelhard
D. Engelhard
HHHans H. Hirsch
Hans H. Hirsch
TLThe Fourth European Conference On Infections In Leukemia
The Fourth European Conference On Infections In Leukemia

26 July 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
DADiana Averbuch
Diana Averbuch
GTGloria Tridello
Gloria Tridello
JHJennifer Hoek
Jennifer Hoek
MMMalgorzata Mikulska
Malgorzata Mikulska
HAHamdi Akan
Hamdi Akan
Simone CesaroSimone Cesaro
Simone Cesaro
This intercontinental study aimed to study gram-negative rod (GNR) resistance in hematopoietic stem cell transplantation (HSCT). GNR bacteremias occurring during 6 months post-HSCT (February 2014–May 2015) were prospectively collected, and analyzed for rates and risk factors for resistance to fluoroquinolones, noncarbapenem anti-Pseudomonas β-lactams (noncarbapenems), carbapenems, and multidrug resistance. Sixty-five HSCT centers from 25 countries in Europe, Australia, and Asia reported data on 655 GNR episodes and 704 pathogens in 591 patients (Enterobacteriaceae, 73%; nonfermentative rods, 24%; and 3% others). Half of GNRs were fluoroquinolone and noncarbapenem resistant; 18.5% carbapenem resistant; 35.2% multidrug resistant. The total resistance rates were higher in allogeneic HSCT (allo-HSCT) vs autologous HSCT (auto-HSCT) patients (P < .001) but similar in community-acquired infections. Noncarbapenem resistance and multidrug resistance were higher in auto-HSCT patients in centers providing vs not providing fluoroquinolone prophylaxis (P < .01). Resistance rates were higher in southeast vs northwest Europe and similar in children and adults, excluding higher fluoroquinolone- and β-lactam/β-lactamase inhibitor resistance rates in allo-HSCT adults. Non-Klebsiella Enterobacteriaceae were rarely carbapenem resistant. Multivariable analysis revealed resistance risk factors in allo-HSCT patients: fluoroquinolone resistance: adult, prolonged neutropenia, breakthrough on fluoroquinolones; noncarbapenem resistance: hospital-acquired infection, breakthrough on noncarbapenems or other antibiotics (excluding fluoroquinolones, noncarbapenems, carbapenems), donor type; carbapenem resistance: breakthrough on carbapenem, longer hospitalization, intensive care unit, previous other antibiotic therapy; multidrug resistance: longer hospitalization, breakthrough on β-lactam/β-lactamase inhibitors, and carbapenems. Inappropriate empiric therapy and mortality were significantly more common in infections caused by resistant bacteria. Our data question the recommendation for fluoroquinolone prophylaxis and call for reassessment of local empiric antibiotic protocols. Knowledge of pathogen-specific resistance enables early appropriate empiric therapy. Monitoring of resistance is crucial. NCT02257931

2 May 2013 in Blood
Verified
Journal Article
Closed access
PDF file
EBEmily Blyth
Emily Blyth
LCLeighton Clancy
Leighton Clancy
RSRenee Simms
Renee Simms
CMChun K. K. Ma
Chun K. K. Ma
JBJane Burgess
Jane Burgess
DGDavid J. Gottlieb
David J. Gottlieb
We investigated the use of adoptively transferred donor-derived cytomegalovirus (CMV) specific cytotoxic T lymphocytes (CTL) as immune reconstitution postallogeneic transplant in a phase 2 study. Fifty patients were infused with a single dose of 2 × 107cells/m2 after day 28 post-transplant. Twenty-six patients reactivated CMV posttransplant (only 5 post-CTL infusion) and 9 required therapy with ganciclovir or foscarnet (only 1 post-CTL infusion). There was 1 case of fatal CMV disease, attributable to high levels of antithymocyte globulin at the time of T cell infusion. We compared the patients in the phase 2 study with a group of contemporaneous controls also treated at the trial centers. There was no increase in acute or chronic graft-versus-host disease attributable to CTL infusion; overall and progression-free survival were similar in both groups. There was a reduction in the percentage of patients who required CMV directed antiviral therapy (17% vs 36%, P = .01) and in the total number of treatment days in the cohort receiving CTL (3.4 days vs 8.9 days, P = .03) without a reduction in CMV reactivation rates. We postulate that adoptively transferred cells are able to expand in response to viral antigen, limit viral replication, and prevent progression to tissue infection. This study was registered on the Australian Clinical Trial Registry as #ACTRN12605000213640 and #ACTRN12607000224426.

21 October 2021 in Blood
Verified
Journal Article
Closed access
PDF file
DBDavid C. Bishop
David C. Bishop
LCLeighton E. Clancy
Leighton E. Clancy
RSRenee Simms
Renee Simms
JBJane Burgess
Jane Burgess
GMGeetha Mathew
Geetha Mathew
KMKenneth Paul Micklethwaite
Kenneth Paul Micklethwaite
Key Points. Matched sibling donor-derived piggyBac CAR T-cells showed 100% CR rate against CD19+ malignancy relapsed/refractory following allo-HSCT.Two cases of